Amgen – Mizuho Securities Stick to Their Hold Rating for Amgen Inc By Fintech Zoom
Mizuho Securities analyst Salim Syed maintained a Hold rating on Amgen Inc (NASDAQ:) on Thursday, setting a price target of $200, which is approximately 20.34% below the present share price of $251.06.
Syed expects Amgen Inc to post earnings per share (EPS) of $3.45 for the first quarter of 2021.
The current consensus among 19 TipRanks analysts is for a Moderate Buy rating of shares in Amgen, with an average price target of $268.44.
The analysts price targets range from a high of $304 to a low of $200.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $6.42 billion and a net profit of $2.45 billion. The company’s market cap is $146.16 billion.
According to TipRanks.com, Mizuho Securities analyst Salim Syed is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.0% and a 49.44% success rate.
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Fintech Zoom or anyone involved with Fintech Zoom will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.